[Associated Press] Medical Groups Question Price Of New Hep C Drug

By Matthew Perrone

March 11, 2014

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.

A panel of California medical experts voted Monday that Gilead’s Sovaldi represents a “low value” treatment, considering its cost compared with older drugs for the blood-borne virus.

[button title=”Read More” link=”http://bigstory.ap.org/article/medical-groups-question-price-new-hep-c-drug” target=”_blank” size=”” color=”” class=””]